🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 14 of 16

  1. Henagliflozin Proline Tablets treatment

    The First People's Hospital of Lianyungang

    Diabetes Type 2

    approved small molecule active

    1 trial

  2. ILUVIEN

    ANI PHARMACEUTICALS INC

    Chronic Diabetic Macular Edema

    approved small molecule completed

    1 trial

  3. ILUVIEN 0.19 MG

    ANI PHARMACEUTICALS INC

    Diabetic Macular Edema (DME)

    approved small molecule completed

    1 trial

  4. INSULIN GLARGINE

    Sanofi-aventis Healthcare Pty Ltd

    Diabetes mellitus II

    approved small molecule active

    1 trial

  5. INSULIN GLARGINE (HOE901)

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule terminated

    1 trial

  6. IVC

    The First People's Hospital of Lianyungang

    Proliferative Diabetic Retinopathy

    approved small molecule active

    1 trial

  7. Iluvien 0.19 MG Drug Implant

    ANI PHARMACEUTICALS INC

    Diabetic Macular Edema

    approved small molecule active

    1 trial

  8. Insulin Glargine

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule completed

    2 trials

  9. Insulin Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  10. Insulin glulisine

    Sanofi Pasteur

    Diabetes Mellitus, Type 1

    approved small molecule completed

    1 trial

  11. Insulin lispro low mixture

    Eli Lilly and Company

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  12. Intravenous Ibuprofen

    CUMBERLAND PHARMACEUTICALS INC

    Obesity

    approved small molecule completed

    1 trial

  13. Intravitreal Aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    approved small molecule terminated

    2 trials

  14. Invokana 100 mg film-coated tablets, Xigduo 5 mg/850 mg film-coated tablets, Vokanamet 150 mg/850 mg film-coated tablets, Forxiga 10 mg film-coated tablets, Vokanamet 50 mg/1,000 mg film-coated tablets, Invokana 300 mg film-coated tablets, Forxiga 5 mg film-coated tablets, Vokanamet 50 mg/850 mg film-coated tablets, Synjardy 12.5 mg/1,000 mg film-coated tablets, Synjardy 12.5 mg/850 mg film-coated tablets, Jardiance 25 mg film-coated tablets, Synjardy 5 mg/1,000 mg film-coated tablets, Xigduo 5 mg/1,000 mg

    Wuhan Createrna Science and Technology Co., Ltd

    Type 2 diabetes mellitus

    approved small molecule active

    1 trial

  15. Kerendia 20 mg film-coated tablets, Kerendia 10 mg film coated tablets, Jardiance 10 mg film-coated tablets

    Disc Medicine

    Albuminuria, Type 2 diabetes

    approved small molecule active

    1 trial

  16. Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution

    NovoThirteen

    Type 2 diabetes

    approved small molecule active

    1 trial

  17. Liraglutide

    Sana Biotechnology

    Morbid Obesity

    approved small molecule completed

    1 trial

  18. Lixisenatide (AVE0010)

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule completed

    3 trials

  19. Maggot debridement therapy

    The First People's Hospital of Lianyungang

    Diabetic Foot Ulcers

    approved other active

    1 trial

  20. Metformin

    Takeda

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  21. Mounjaro 5 mg solution for injection in pre-filled pen, Mounjaro 2.5 mg solution for injection in pre-filled pen

    The George Institute

    Obesity

    approved small molecule active

    1 trial

  22. Mysimba 8 mg/90 mg prolonged-release tablets

    Disc Medicine

    Obesity, Obesity Surgery

    approved small molecule active

    1 trial

  23. NESINA ACT TAB. 25/15mg

    Takeda

    Diabetes

    approved small molecule active

    1 trial

  24. Nocardia rubra Cell Wall Skeleton

    The First People's Hospital of Lianyungang

    Diabetic Foot Ulcer

    approved small molecule active

    1 trial

  25. Optimal hypoglycemic treatment

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved other active

    1 trial

  26. Ozempic 1 mg solution for injection in pre-filled pen, Dapagliflozin 10 mg film-coated tablets

    The George Institute

    Type 2 diabetes

    approved small molecule active

    1 trial

  27. Ozempic 1 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

    Disc Medicine

    Diabetic foot ulcer

    approved small molecule active

    1 trial

  28. Pharmacotherapy

    The First People's Hospital of Lianyungang

    Diabetes Mellitus, Type 2

    approved small molecule active

    1 trial

  29. Pioglitazone

    Takeda

    Diabetes Type 2

    approved small molecule completed

    1 trial

  30. Pioglitazone

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    9 trials

  31. Pioglitazone

    Takeda

    Obesity

    approved small molecule completed

    1 trial

  32. Pioglitazone

    Takeda

    Type II Diabetes Mellitus

    approved small molecule completed

    1 trial

  33. Pioglitazone

    Takeda

    Metabolic Syndrome

    approved small molecule completed

    1 trial

  34. Pioglitazone

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule completed

    2 trials

  35. Pioglitazone and Metformin

    Disc Medicine

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  36. Pioglitazone and insulin

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    2 trials

  37. Pioglitazone and metformin

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    5 trials

  38. Pioglitazone then Placebo

    Takeda

    Diabetes

    approved small molecule completed

    1 trial

  39. Placebo of vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  40. Plasma rich in growth factors

    Wuhan Createrna Science and Technology Co., Ltd

    Foot ulcers in diabetic patients with peripheral arterial disease

    approved small molecule active

    1 trial

  41. Pregabalin

    Yung NA

    Diabetic Peripheral Neuropathy

    approved small molecule completed

    1 trial

  42. RIMEGEPANT , Capsaicin

    Disc Medicine

    Obesity, Migraine

    approved small molecule active

    1 trial

  43. Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial

  44. Rapid Acting insulin with pre-treatment of rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  45. Renin-angiotensin system blockers

    Hospital Authority, Hong Kong

    Diabetes

    approved small molecule active

    1 trial

  46. SEMAGLUTIDE, SEMAGLUTIDE, INSULIN GLARGINE, DAPAGLIFLOZIN

    Fondazione Telethon ETS

    type 2 diabetes

    approved small molecule active

    1 trial

  47. SGLT2 inhibitor

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved small molecule active

    1 trial

  48. SGLT2 inhibitor (Empagliflozin 25 MG)

    Hospital Authority, Hong Kong

    Type2 Diabetes

    approved small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.